Abstract

POTENTIAL TARGET THERAPY AND DRUG TREATMENT FOR PARKINSON’S DISEASE

Ankita Bhardwaj, Diksha Sharma* and Dr. Kapil Kumar Verma

.

Abstract

Parkinson disease (PD) is a neurodegenerative condition that worsens over time and is mostly caused by the death of dopaminergic neurons in the substantia nigra. This loss results in bradykinesia, rigidity, and tremors, among other motor symptoms. Disease-modifying medicines are still needed, despite advances in treating symptoms. Beyond dopamine substitution, novel research is increasingly concentrating on possible treatment targets. Over 6 million people globally suffer with Parkinson's disease. PD is characterized by motor impairments that are linked to the gradual death and degradation of dopaminergic neurons in the pars compacta the majority of patients can only access or benefit from the most widely used PD treatments, which are either partially or momentarily effective. More potent treatments are desperately needed because current ones neither stop the disease's progression nor replace lost or degraded dopaminergic neurons. We offer a thorough review of the state of knowledge on the molecular signaling pathways connected to Parkinson's disease (PD), with a focus on how environmental and genetic factors influence the development and course of the disease. Additionally emphasized are the roles played by proteasome systems, autophagy-lysosomal pathways, and molecular chaperones in Parkinson's disease. Furthermore, new treatment approaches to stop or slow the advancement of this complicated illness are examined, including gene therapy, stem cell transplantation, pharmaceutical interventions, and complementary, supportive, and rehabilitation therapies.

Keywords: Cell treatment, Parkinson's disease, misfolded proteins, neurodegeneration, Cell therapy.